Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Eisai's digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed at improving the management of dementia. The smartphone app – which uses a ...

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US. The anti-amyloid ...

NHSA of China adds generic lecanemab in its commercial insurance innovative drug list to treat early Alzheimer’s disease: Tokyo Thursday, December 11, 2025, 16:00 Hrs [IST] Toky ...

Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...

Experts concluded the drug, which slows the progression of the disease for some people, did not have therapeutic value ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

A new study published in Addiction has identified genetic factors that influence both a person’s risk of developing an addiction and their educational attainment. Researchers found that some genetic ...

Pfizer deals again in obesity space as Wave and Structure drop splashy weight loss results; what CDER Director Richard Pazdur ...

On Oct. 10, Trump received an MRI at Walter Reed Medical Center, which is typically not needed for a regular physical ...